Daa Pangenotypic Mavyret denied due to quantity / dose limits by Aetna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for daa pangenotypic mavyret are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Daa Pangenotypic Mavyret
## Why Aetna Applies Quantity Limits to Mavyret
Aetna's formulary management includes quantity-limit (QL) controls on specialty medications. For Mavyret (glecaprevir/pibrentasvir), quantity limits typically correspond to the treatment-duration parameters described in the FDA-approved prescribing label — which varies based on genotype, presence of cirrhosis, and prior treatment history. A QL denial usually means the quantity requested exceeds the default limit set in Aetna's system, even when the prescriber's order is entirely consistent with the FDA-approved label for the patient's specific clinical profile.
## Why This Denial Is Appealable
A quantity-limit denial is appealable whenever the requested quantity is supported by the FDA-approved prescribing label for the patient's documented clinical situation. The FDA label — not Aetna's system default — is the authoritative source for appropriate treatment duration. If your prescriber's order reflects the label-supported duration for your genotype and disease stage, the QL denial lacks a clinical basis.
## Federal Appeal Framework
- ACA §2719 / ERISA §503: Quantity-limit denials are reviewable through internal appeal and, if necessary, independent external review.
- Timeline: Internal appeal must generally be filed within 180 days of the denial. External review is available within approximately 4 months of an internal denial.
- Expedited option: If delay would seriously jeopardize your health, request an expedited review with a decision typically required within 72 hours.
## The Appeal Process
1. Obtain the exact QL that Aetna applied and the quantity your prescriber ordered. 2. Identify the corresponding treatment-duration section in the FDA-approved Mavyret prescribing label for your genotype and clinical profile. 3. Have your prescriber document in a letter why the requested quantity matches the label-supported duration for your specific case. 4. Submit the internal appeal with the prescriber letter, the relevant section of the FDA label, and the clinical documentation below. 5. If denied, request independent external review — a reviewer applying FDA-label standards is well-positioned to overturn a QL denial based on label-supported duration.
## Documentation to Gather
- Genotype result: Laboratory confirmation of HCV genotype, which directly determines label-supported duration.
- Cirrhosis/fibrosis status: Chart documentation of liver disease stage, as this affects label-recommended treatment length.
- Treatment history: Prior HCV therapy dates and outcomes — treatment-experienced status may extend the label-supported duration.
- Prescriber letter: Explains the specific clinical factors (genotype, cirrhosis status, treatment history) that require the requested quantity, citing the FDA label.
- FDA prescribing label excerpt: The relevant duration table from the current Mavyret label (available at DailyMed).
## Criteria-Mapping Structure
Build a two-column table: left column lists Aetna's quantity-limit policy criteria and the relevant FDA label duration parameters; right column maps each to the patient's genotype result, fibrosis staging, and treatment history. Show explicitly that the requested quantity equals — and does not exceed — the label-supported duration for this patient's documented profile.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →